TONIX Pharmaceuticals to Present at the New York Society of Security Analysts’ 15th Annual Biotech and Specialty Pha

NEW YORK--(BUSINESS WIRE)-- Tonix Pharmaceuticals Holding Corp. (OTCBB: TNXP) (“TONIX”), a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system (“CNS”), including fibromyalgia syndrome (“FM”) and post-traumatic stress disorder (“PTSD”), will be presenting at the 15th Annual Biotech and Specialty Pharmaceuticals Conference on November 30, 2011 at 2:10 p.m. EST.

Seth Lederman, M.D., Chairman and President of TONIX, will present an overview of the company and discuss its clinical development and business strategy. A live webcast of the presentation will be available, and can be accessed at the following link:

http://investor.shareholder.com/media/eventdetail.cfm?eventid=105790&CompanyID=AMDA-MOBC8&e=1&mediaKey=BD548813454BD29699ADA017C4E3AC7E

About TONIX Pharmaceuticals

TONIX Pharmaceuticals is developing new therapies for challenging disorders of the central nervous system. The Company targets conditions characterized by significant unmet medical need, inadequate existing treatment options, and high dissatisfaction among both patients and physicians. TONIX reformulates approved pharmaceutical active ingredients to design products with optimal safety, efficacy and predictability. Its most advanced product candidates, TNX-102 for FM and TNX-105 for PTSD, are novel dosage formulation of cyclobenzaprine, the active ingredient in two U.S. FDA-approved muscle relaxants. To learn more about the Company and its pipeline of treatments for CNS conditions, please visit www.tonixpharma.com.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as "anticipate," "believe," "forecast," "estimated" and "intend," among others. These forward-looking statements are based on TONIX’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; uncertainties of government or third party payer reimbursement; limited sales and marketing efforts and dependence upon third parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any pharmaceutical under development, there are significant risks in the development, regulatory approval and commercialization of new products. TONIX does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in the Current Report on Form 8-K filed with the SEC on October 14, 2011 and future periodic reports filed with the Securities and Exchange Commission. All of the Company's forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date hereof.



CONTACT:

TONIX Pharmaceuticals, Inc.
Benjamin Selzer, 212-980-9155
Chief Operating Officer
or
Porter, LeVay & Rose, Inc.
Sharon Weinstein, Investor Relations
or
Bill Gordon, Media Relations
212-564-4700

KEYWORDS:   United States  North America  New York

INDUSTRY KEYWORDS:   Health  Biotechnology  Pharmaceutical  Professional Services  Finance  Communications  Public Relations/Investor Relations

MEDIA:

Logo Image removed.
Read more on